disulfiram has been researched along with Carcinoma, Renal Cell in 2 studies
Carcinoma, Renal Cell: A heterogeneous group of sporadic or hereditary carcinoma derived from cells of the KIDNEYS. There are several subtypes including the clear cells, the papillary, the chromophobe, the collecting duct, the spindle cells (sarcomatoid), or mixed cell-type carcinoma.
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 2 (100.00) | 2.80 |
Authors | Studies |
---|---|
Ni, X | 1 |
Ye, C | 1 |
Yu, X | 1 |
Zhang, Y | 1 |
Hou, Y | 1 |
Zheng, Q | 1 |
Chen, Z | 1 |
Wang, L | 1 |
Weng, X | 1 |
Yang, C | 1 |
Liu, X | 1 |
Yoshino, H | 1 |
Yamada, Y | 1 |
Enokida, H | 1 |
Osako, Y | 1 |
Tsuruda, M | 1 |
Kuroshima, K | 1 |
Sakaguchi, T | 1 |
Sugita, S | 1 |
Tatarano, S | 1 |
Nakagawa, M | 1 |
2 other studies available for disulfiram and Carcinoma, Renal Cell
Article | Year |
---|---|
Overcoming the compensatory increase in NRF2 induced by NPL4 inhibition enhances disulfiram/copper-induced oxidative stress and ferroptosis in renal cell carcinoma.
Topics: Animals; Carcinoma, Renal Cell; Copper; Disulfiram; Ferroptosis; Kidney Neoplasms; Mice; NF-E2-Relat | 2023 |
Targeting NPL4 via drug repositioning using disulfiram for the treatment of clear cell renal cell carcinoma.
Topics: Acetaldehyde Dehydrogenase Inhibitors; Animals; Apoptosis; Biomarkers, Tumor; Carcinoma, Renal Cell; | 2020 |